JP Morgan Reinstates Neutral on NovoCure, Announces $17 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 76.2%

Neg 0% Neu 76.2% Pos 0%

JP Morgan analyst Jessica Fye reinstates NovoCure (NASDAQ:NVCR) with a Neutral and announces $17 price target.

Comments

No comments yet. Be the first!